BioNxt Solutions Inc.
15.8.2024 22:04:41 CEST | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / August 15, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a non-binding letter of intent (the "LOI") with German-based international contract research, development, and manufacturing company Gen-Plus GmbH & Co KG ("Gen-Plus"), a part of Conscio Group.
Further to the Master Service Agreement and Cladribine Statement of Work signed by BioNxt and Gen-Plus announced on July 9, 2024, and July 17, 2024, respectively, the LOI recognizes a number of important areas of potential cooperation between the parties, including but not limited to intellectual property and prototype development for new pharmaceutical products, clinical trial planning and batch manufacturing, laboratory, equipment, and office collaboration, business development, and thin film commercial manufacturing. The Company will provide further details on specific cooperation programs as they progress.
Gen-Plus, a part of Conscio Group, has a head office in Munich, Germany, and through the Conscio Group operates within an international network of pharmaceutical service providers with facilities in five countries and over 500 employees. They offer GCP/GLP/GMP/ISO/IEC-certified services and GMP certified manufacturing of clinical trial supplies (Phase I-III) with a specialization in solids, semi-solids, liquids, oral films, and transdermal patches as well as integrated lab analytical services during development & GMP manufacturing, including API characterization, method development, optimization, validation, permeation studies, stabilities studies, etc.
BioNxt is developing a 100% owned and proprietary ODF Cladribine dosage form, directed at the multiple sclerosis ("MS") market. Cladribine tablets are currently approved for use in over 75 countries, including by the United States Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA"), with annual sales in excess of one billion USD. Cladribine tablets are approved for several indications, namely highly active forms of relapsing-remitting MS and certain forms of leukemia. MS represents the largest market segment for the sale of Cladribine with approximately 2.3 million people living with MS worldwide, with the highest prevalence in North America and Europe, noted by Atlas of MS. The global Multiple Sclerosis drug market is expected to top USD 41 billion by 2033 according to Market.us.
The Company has filed Cladribine ODF-related provisional patent applications with three to four patent applications expected to be on file in major international jurisdictions by late 2024 to early 2025 with potential patent protection extending to 2044.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
BioNxt Solutions Inc.
Wolfgang Probst, CEO and Director
Email: info@bionxt.com
Phone: +1 780-818-6422
Cautionary Statement Regarding "Forward-Looking" Information
Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as "expects", "intends", "is expected", "potential", "suggests" or variations of such words or phrases, or statements that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company's control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X Reports $60.8 Million in Nine-Month Revenue and Files Q3 Form 10-Q21.4.2026 17:40:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / April 21, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the nine months ended February 28, 2026. The filing reflects Karbon-X's continued expansion in global carbon markets, with year-to-date revenue of $60.8 million, a strengthened balance sheet, and a growing project pipeline, supported by increasing demand for high-integrity carbon solutions. "Karbon-X has scaled significantly over the past twelve months, with nine-month revenue of $60.8 million reflecting strong commercial execution across our trading operations," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "While Q3 trading volumes reflected expected variability in settlement timing across international markets, our underlying business continues to strengthen. We remain focused on disciplined growth across trading, project development, and dig
Karbon-X Reports $60.8 Million in Nine-Month Revenue and Files Q3 Form 10-Q21.4.2026 17:40:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / April 21, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the nine months ended February 28, 2026. The filing reflects Karbon-X's continued expansion in global carbon markets, with year-to-date revenue of $60.8 million, a strengthened balance sheet, and a growing project pipeline, supported by increasing demand for high-integrity carbon solutions. "Karbon-X has scaled significantly over the past twelve months, with nine-month revenue of $60.8 million reflecting strong commercial execution across our trading operations," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "While Q3 trading volumes reflected expected variability in settlement timing across international markets, our underlying business continues to strengthen. We remain focused on disciplined growth across trading, project development, and dig
Graid Technology Launches Agentic AI Storage Portfolio to Eliminate KV Cache Bottlenecks21.4.2026 17:00:00 CEST | Press release
From edge inference to NVIDIA STX, purpose-built KV cache infrastructure for consistent performance at scale. SUNNYVALE, CA / ACCESS Newswire / April 21, 2026 / Graid Technology, the pioneer in GPU-accelerated NVMe storage, today announced its Agentic AI Storage Portfolio: a purpose-built family of KV cache solutions designed to eliminate the storage bottleneck that stalls "always-on" production AI. The portfolio spans three deployment tiers: KV Cache Server, KV Cache Rack, and KV Cache Platform, all built on SupremeRAID™ technology. KV Cache Platform, the portfolio's highest tier, is purpose-aligned to NVIDIA's STX reference architecture, with native BlueField-4 DPU execution on the roadmap for H2 2026. As agentic AI moves from experimentation to production, the infrastructure assumptions that underpinned single-shot inference have broken down. Models running continuous multi-step tasks and maintaining context across hours of operation generate KV cache demands that overwhelm GPU HBM.
Graid Technology Launches Agentic AI Storage Portfolio to Eliminate KV Cache Bottlenecks21.4.2026 17:00:00 CEST | Press release
From edge inference to NVIDIA STX, purpose-built KV cache infrastructure for consistent performance at scale. SUNNYVALE, CA / ACCESS Newswire / April 21, 2026 / Graid Technology, the pioneer in GPU-accelerated NVMe storage, today announced its Agentic AI Storage Portfolio: a purpose-built family of KV cache solutions designed to eliminate the storage bottleneck that stalls "always-on" production AI. The portfolio spans three deployment tiers: KV Cache Server, KV Cache Rack, and KV Cache Platform, all built on SupremeRAID™ technology. KV Cache Platform, the portfolio's highest tier, is purpose-aligned to NVIDIA's STX reference architecture, with native BlueField-4 DPU execution on the roadmap for H2 2026. As agentic AI moves from experimentation to production, the infrastructure assumptions that underpinned single-shot inference have broken down. Models running continuous multi-step tasks and maintaining context across hours of operation generate KV cache demands that overwhelm GPU HBM.
87% of HR Leaders Have Conducted or Plan Layoffs in 2026. New LHH Research Reveals How Integrated Outplacement and Targeted Redeployment Protect Future Talent and Support Those Who Must Leave21.4.2026 14:07:00 CEST | Press release
Only 19% of employees recognize redeployment programs that 77% of HR leaders say exist, revealing a critical visibility gap that prevents organizations from retaining future-critical talent and fulfilling their duty of care to departing employees. NEW YORK CITY, NY / ACCESS Newswire / April 21, 2026 / New research from LHH, a global talent solutions provider and business unit of the Adecco Group, finds that 87% of HR leaders say their organization has already conducted or is planning layoffs in the next 12 months, driven by skills displacement, AI transformation, and shifting market demands. At the same time, 62% of employers track rehiring costs and nearly three quarters of those organizations acknowledge that rehiring costs are more than targeted redeployment and mobility. The findings, published in LHH's The Mobility Breakdown: Redeployment and Outplacement Trends Report reveal that as workforce restructuring becomes continuous, most organizations lack integrated outplacement and ta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom